FDA Adverse Event Injury Summary report: N

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 1800534 · Received August 12, 2010

Report

Report Number
2024168-2010-01644
Event Type
Injury
Date Received
August 12, 2010
Date of Event
July 11, 2010
Report Date
July 19, 2010
Manufacturer
ABBOTT VASCULAR-CARDIAC THERAPIES
Product Code
NIQ
PMA / PMN Number
P070015
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
MS, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). ANGINA AND RESTENOSIS ARE KNOWN ADVERSE EVENTS AS LISTED IN THE XIENCE V INSTRUCTIONS FOR USE. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECTS AND THE RELATIONSHIP TO THE DEVICE, IF ANY, CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURE OR DESIGN. ALL STENT DELIVERY SYSTEMS ARE SUBJECTED TO A 100% VISUAL INSPECTION. IN ADDITION, A QUALITY CONTROL AUDIT INSPECTION IS USED TO VERIFY THE PRODUCT QUALITY.

Description of Event or Problem · 1

DEVICE ISSUE: NONE. ADVERSE EVENT: RESTENOSIS REQUIRING INTERVENTION. TIME OF ADVERSE EVENT: APPROXIMATELY 22 MONTHS AFTER THE PROCEDURE. IT WAS REPORTED VIA TRIAL THAT ON (B)(6) 2008, THE PATIENT UNDERWENT STENTING IN THE PREDILATED MID RIGHT CORONARY ARTERY WITH ONE XIENCE V STENT. ON (B)(6) 2010, THE PATIENT EXPERIENCED UNSTABLE ANGINA THAT WAS TREATED WITH INTRAVENOUS NITROGLYCERIN. THE PATIENT UNDERWENT A DIAGNOSTIC CORONARY ANGIOGRAM THAT FOUND A NEW LESION PROXIMAL TO THE INDEX STENT THAT EXTENDED INTO THE PROXIMAL TIP OF THE STENT WITH AN APPROXIMATE 75% STENOSIS. THIS LESION WAS REVASCULARIZED WITH PERCUTANEOUS CORONARY INTERVENTION. THE PATIENT'S CONDITION RESOLVED ON (B)(6) 2010. THERE WAS NO ADVERSE PATIENT SEQUELA. THERE WAS NO ADDITIONAL INFORMATION PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM NIQ ABBOTT VASCULAR-CARDIAC THERAPIES NA 8051461

Patients

Seq Age Sex Outcome Treatment
1 71 YR Hospitalization| R